Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $196
AbbVie, Inc. -0.85%
AbbVie, Inc. ABBV | 172.43 | -0.85% |
Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:
ABBV) with a Overweight and raises the price target from $193 to $196.
